by Sean Hughes | Mar 1, 2018 | Briefings, US & International
Europe The Enlarged Board of Appeal in G 02/08 clarified that second medical use claims to new and inventive dosage regimes are patentable, even where the substance or composition, and the disease to be treated, are the same as in the prior art. Nevertheless, the...
by Alex Bajjon | Nov 1, 2017 | US & International
The Case In 2016, Fresenius requested a declaration of non-infringement in Italy for its pemetrexed diacid product in respect of Lilly’s European patent EP1313508. Lilly’s patent was amended during prosecution to specify in claim 1 that pemetrexed disodium...
by Juliette Boynton | Aug 1, 2017 | US & International
In 2010 Apotex started to sell a generic version of this drug and AstraZeneca brought an action against Apotex for patent infringement. In response Apotex counter-claimed to have the patent declared invalid. In the first instance decision the Judge held that the...
by George Schlich | Aug 1, 2017 | EPO
Introduction Of all people involved in the filing, prosecution and enforcement of patent rights, it could be argued that none are as important as the drafters of the initial application. Regardless of the skill and experience of the litigators, certain errors or...
by Carolyn Haywood | Aug 1, 2017 | Briefings, UK
The recent interim Patents Court decision of Napp Pharmaceutical Holdings Limited v (1) Dr Reddy’s Laboratories (2) Sandoz Limited (and others) [2017] EWHC 1433 (Pat) provides guidance on how the court calculates damages associated with an interim injunction and...
Recent Comments